Pfizer Inc
PFE#132 of 134 by buybacksNYSE · Healthcare · Drug Manufacturers - General · USA
pfizer.comBuybacks · FY2025—latest fiscal year
Buyback yield—repurchases ÷ market cap
Dividends · FY2025$9.77Bdividend yield 6.1%
Shareholder yield6.1%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−1.2%5.70B shares (2026)
Buybacks ÷ free cash flown/anot meaningful for this company
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | — | $9.77B | $9.08B |
| FY2024Dec 2024 | $0 | $9.51B | $9.84B |
| FY2023Dec 2023 | $0 | $9.25B | $4.79B |
| FY2022Dec 2022 | $2.00B | $8.98B | $26.0B |
| FY2021Dec 2021 | $0 | $8.73B | $29.9B |
| FY2020Dec 2020 | −$425M | $8.44B | $11.6B |
| FY2019Dec 2019 | $8.87B | $8.04B | $9.99B |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the…
- Market cap
- $161B
- P/E (trailing)
- 37.2×
- Fiscal year end
- December
- ISIN
- US7170811035
- Reporting currency
- USD
- Data updated
- Oct 10, 2026